ArticlePLOS global public health2026
Mapping the research, policy, and clinical management landscape of post-tuberculosis lung disease: A scoping review.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) can result in debilitating long-term health consequences, most notably post-tuberculosis lung disease (PTLD). However, these conditions remain insufficiently integrated into global policy and routine care, contributing to fragmented care for millions of TB survivors. This scoping review maps the current landscape to identify critical gaps and support the harmonisation of research, policy, and practice. We conducted a scoping review of peer-reviewed research and global guidance documents published between June 2017 and May 2025. The search for peer-reviewed research focused specifically on PTLD management, whereas the search for guidance documents used broader terms for post-tuberculosis (post-TB) sequelae to assess how PTLD is conceptualised within the wider policy context. Data on recognition, management recommendations, and classification were systematically extracted and thematically synthesised. We included 28 documents: 14 research publications and 14 global guidance documents. The research literature offered detailed management content, including diagnostic assessment, pulmonary rehabilitation and chronic care approaches, acute-on-chronic complication management, and follow-up schedules. In contrast, only 8 of 14 guidance documents provided management recommendations relevant to PTLD. Recurring guidance recommendations included structured post-TB respiratory assessment, multidisciplinary care incorporating rehabilitation and psychosocial support, and clinical, radiological, and functional follow-up, whereas acute-on-chronic management was addressed far less consistently. Overall, we found a translation gap between evidence generation in research and its operationalisation in global guidance. Despite growing awareness and some recent policy progress, the global response to PTLD remains hampered by inconsistent and incompletely operationalised guidance, as well as the absence of standardised definitions, classification, and programmatic indicators. Accelerating the translation of research into integrated policy and practice is needed to improve the long-term health and quality of life of TB survivors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.